Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21566643 | 0.83 | POLB (0.41) | POLBL3MBTL1HSD11B1MEN1KMT2A | |
| SCHEMBL9962271 | 0.82 | ALDH1A1 (0.51) | POLBL3MBTL1HSD11B1HTTALDH1A1 | |
| SCHEMBL3925077 | 0.78 | POLB (0.43) | POLBL3MBTL1HSD11B1CYP1A2HIF1A | |
| SCHEMBL4566032 | 0.77 | HCRTR2 (0.48) | POLBL3MBTL1HSD11B1MEN1KMT2A | |
| SCHEMBL31344705 | 0.77 | HSD11B1 (0.44) | POLBL3MBTL1HSD11B1CYP1A2CYP2C19 | |
| SCHEMBL19287742 | 0.76 | SLC6A2 (0.39) | POLBHSD11B1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL10179614 | 0.76 | PSIP1 (0.45) | POLBL3MBTL1HSD11B1CYP1A2HIF1A | |
| SCHEMBL12077718 | 0.75 | PGR (0.49) | L3MBTL1HSD11B1MEN1KMT2ACYP1A2 | |
| SCHEMBL13395312 | 0.75 | GAA (0.50) | L3MBTL1MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL19287839 | 0.74 | SIGMAR1 (0.54) | L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | POLB 1335/4885L3MBTL1 1733/4885HSD11B1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.